This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pfizer Gains on Test Data

Shares of Pfizer (PFE - Get Report) rose Tuesday after the company announced that test results for an experimental stomach cancer drug were so good that the study was halted.

The study of the drug SU11248 was halted seven months ahead of schedule on the recommendation of an independent group of scientists monitoring the research. The recommendation was made in late January.

The study compared patients receiving a placebo vs. patients receiving the drug for gastrointestinal stromal tumor, or GIST. The placebo patients were given the option of taking the experimental drug once the test was halted.

"We are encouraged by this interim data analysis and believe this is a positive step towards establishing SU11248 as an option for patients with Gleevec-resistant GIST," said Dr. Joseph Feczko, Pfizer president of worldwide development. Gleevec is a cancer drug sold by Novartis (NVS - Get Report).

"Pfizer and study investigators are working together to provide SU11248 to those enrolled in the study as quickly as possible and hope this unique therapy will continue to provide meaningful clinical benefit for cancer patients," he said.

The phase III test of the drug is the last in a series of clinical trials before a company submits a drug application to the Food and Drug Administration. Pfizer also is conducting a phase III test of the drug for kidney cancer. The drug launches a two-pronged assault on cancer -- attacking tumors and choking off the blood supply to tumors to prevent their growth.

Pfizer's stock was up 75 cents, or 3%, to $25.66.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
NVS $75.74 -1.40%
PFE $32.57 -1.00%
AAPL $93.28 -1.60%
FB $116.91 0.15%
GOOG $691.66 0.09%


Chart of I:DJI
DOW 17,711.19 -119.57 -0.67%
S&P 500 2,055.29 -20.52 -0.99%
NASDAQ 4,754.2870 -51.0040 -1.06%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs